Loading
A phase 2 trial of HS-10365 capsules in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06147570 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 62 participants planned, started 2023-09-25 and due to reach its primary completion in 2027-08-31. Interventions recorded: HS-10365 capsules.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares RET, Non-small-cell lung cancer and the tag pipeline.
Shares RET fusion-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/